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https://doi.org/10.1016/j.stemcr.2021.06.016SUMMARYThe generation of inducible pluripotent stem cells (iPSCs) is a revolutionary technique allowing production of pluripotent patient-spe-
cific cell lines used for disease modeling, drug screening, and cell therapy. Integrity of nuclear DNA (nDNA) is mandatory to allow iPSCs
utilization, while quality control of mitochondrial DNA (mtDNA) is rarely included in the iPSCs validation process. In this study, we per-
formed mtDNA deep sequencing during the transition from parental fibroblasts to reprogrammed iPSC and to differentiated neuronal
precursor cells (NPCs) obtained from controls and patients affected bymitochondrial disorders. At each step, mtDNAvariants, including
those potentially pathogenic, fluctuate between emerging and disappearing, and some having functional implications. We strongly
recommend including mtDNA analysis as an unavoidable assay to obtain fully certified usable iPSCs and NPCs.INTRODUCTION
The exponential increase of applications of induced plurip-
otent stem cells (iPSCs) includes generation of differenti-
ated cells, development of organoids for investigations of
disease mechanisms and drug discovery (Shi et al., 2017),
and their clinical use for therapeutic purposes in humans
(Barker et al., 2017). This poses specific questions on their
quality control, and there are concerns about age-related
burden of somatic mutations (Kang et al., 2016; Lo Sardo
et al., 2017), lineage-specific epigenetic memory affecting
the methylation pattern (Nashun et al., 2015), and pre-ex-
isting or reprogramming-related occurrence of tumorigenic
mutations (Ben-David and Benvenisty, 2011; Gore et al.,
2011). Such concerns have recently hampered and
currently limit the therapeutic use of autologous iPSCs
(Garber, 2015).
One area of genetic variability affecting the quality of
iPSCs is mitochondrial DNA (mtDNA), a small, circular,
multicopy, double-stranded molecule of DNAwithin mito-
chondria, which has a mutagenesis rate much higher than
nuclear DNA (Gustafsson et al., 2016; Wallace, 2015). The
mtDNA hosts hundreds of pathogenic mutations causing
a vast variety of clinical phenotypes (La Morgia et al.,Stem Cell Repor
This is an open access arti2020) characterized by defective oxidative phosphoryla-
tion (OXPHOS), increased oxidative stress, calcium mis-
handling, propensity to apoptosis, altered organelle dy-
namics, and removal by autophagy (Nunnari and
Suomalainen, 2012). Furthermore, mtDNA genetics fol-
lows peculiar rules: maternal inheritance, homo-hetero-
polyplasmy, mitotic segregation and threshold effect,
germline bottleneck, and individual cell clonal expansion
of mutant molecules. All these mtDNA features are re-
flected in higher-order complexities when it comes to
global function of individual cells, including iPSCs (Xu
et al., 2013). Of particular relevance is the potential func-
tional reflection on iPSCs of mtDNA sequence diversity
characterizing human populations (Gómez-Durán et al.,
2010; Strobbe et al., 2018).
A few studies clearly highlighted the major impact that
mtDNA mutagenesis may have on iPSC quality (Kang
et al., 2016; Lorenz and Prigione, 2016; Perales-Clemente
et al., 2016; Prigione et al., 2011; Zambelli et al., 2018). Crit-
ical issues are the clonal expansion in single cells of private
heteroplasmic mtDNA variants as part of the so-called uni-
versal heteroplasmy (Payne et al., 2013), the possible de
novo mtDNA mutagenesis occurring during cycling of the
parental cell line, the possible mtDNA mutagenesis relatedts j Vol. 16 j 1953–1967 j August 10, 2021 j ª 2021 The Author(s). 1953
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to cell reprogramming, and the bottleneck effects and ge-
netic drifts due to themtDNA copy number reduction char-
acterizing iPSCs (Bukowiecki et al., 2014; Xu et al., 2013).
All these possibilities remain open questions, and previous
studies have reached contradictory results. The introduc-
tion of deep next-generation sequencing (NGS) has low-
ered the detection limit of heteroplasmy to 0.2%, and
different studies demonstrated that low-level heteroplasmy
(down to 0.1%)may be transmitted andmaintainedwithin
families (Giuliani et al., 2014; Guo et al., 2013).
We present our own analysis of iPSCs generated from fi-
broblasts and peripheral blood mononuclear cells (PBMCs)
and, for the first time, of neuronal precursor cells (NPCs).
We performed mtDNA deep sequencing in fibroblasts/
iPSCs/NPCs obtained from controls and two classes of pa-
tients: a mitochondrial group carrying known homoplas-
mic or heteroplasmic mtDNA mutations and a nuclear
group carryingmutations in nuclear genes coding formito-
chondrial proteins.RESULTS
Deep sequencing of mtDNA
WeperformedmtDNAdeep sequencing in 17 fibroblast cell
lines, one PBMC cell line, 35 iPSCs clones, and 16 NPCs,
belonging to the three categories: controls (C1 to C5) (Fig-
ure S1A), mitochondrial (M1 to M6) (Figure S1B), and nu-
clear (N1 to N7) patients (Figure S1C) (Table 1). A median
coverage of 14,978X (±4,731X), 7,138X (±3,269X), and
6,172X (±2,551X) was respectively achieved in fibro-
blasts/PBMCs, iPSCs, and NPCs (Table S1). In some cases,
we observed a coverage reduction for certain mtDNA re-
gions and we checked for the presence of macrodeletions
by analyzing the sequencing data with the MitoSAlt tool
(https://sourceforge.net/projects/mitosalt/) (Basu et al.,
2020). No macrodeletions were observed with hetero-
plasmy levels higher than 1%. This result was further sup-
ported by the analysis with digital droplet PCR, on the
same cell lines carrying OPA1 mutations here investigated
and previously published (Iannielli et al., 2018).
Variants were analyzed with PhyloTree (https://www.
phylotree.org/tree/index.htm) to reconstruct the hap-
logroup of each cell line and the full consistency of haplo-
types between parental fibroblasts, iPSCs derived clones,
and correlated NPCs (Table 1). All haplogroups were com-
mon to the population of European ancestry (H, J, U),
except one control cell line (C5) carrying the D1g haplo-
type. We analyzed only private single nucleotide mtDNA
variants, not belonging to the specific haplogroup. We
traced their segregation during reprogramming and differ-
entiation to assess the change in heteroplasmy fraction
(HF) and screened for possible novel damaging variants.1954 Stem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021Impact of age, reprogramming methods, and
mitochondrial haplotype on abundance of mtDNA
variants in fibroblasts, iPSCs, and NPCs
In our study, the age range of subjects was wide (12–80
years) andwe investigated the impact of age on the number
of mtDNA variants. The average number of variants in fi-
broblasts from older subjects (R50 years old) was signifi-
cantly higher compared with younger subjects (Figure 1A).
Moreover, there was a linear correlation (Figure 1B) be-
tween ages and somatic mtDNA variability accumulated
in fibroblasts. In contrast, we did not observe a greater
number of mtDNA variants (Figure 1A) either in the iPSCs
or in the NPCs in the older group. Similarly, the age-related
variants burden was progressively lesser and gradually
dropped in each cell stage (Figure 1B).
We here employed three reprogramming procedures:
Sendai virus in 14 cell lines, retroviral transduction in three
lines, and an episomal plasmid in the remaining one (M4,
Table 1). We did not observe a significant effect of a specific
reprogramming method on the number of mtDNA hetero-
plasmic variants either in iPSCs or in NPCs (Figure 1C).
We also evaluated the effect of mitochondrial haplotypes,
specifically J, H, and U, on the burden of mtDNA variants,
excluding the D1g haplotype, present in a single cell line.
The number of variants in fibroblasts and NPCs was not
related to a specific haplotype, while haplotype J turned
out to have significantly fewer variants in iPSCs (Figure 1D).
mtDNA heteroplasmy and variants segregations from
parental fibroblasts to iPSCs
The analysis of private variants showed a high frequency of
heteroplasmy in the three groups for a total of 120 hetero-
plasmic variants; the mitogenomes of the patients’ groups
did not harbor a higher number of variants in both fibro-
blasts (p = 0.082) and iPSCs (p = 0.234) (not shown). More-
over, in iPSCs, we observed a wide range of segregation
models of the fibroblast variants (Figures S3 and S4):
some iPSC clones completely lost the parental fibroblast
variants, presenting (Figures S2G, S3D, S4C, and S4K) or
not (Figures S2A and S4B) their own unique variants. Other
iPSC clones harbored entirely (Figures S2F and S4A) or in
part (Figures S2A, S2B, S2D, S3B, S3E, S3F, S4D, and S4E)
only the variants present in their parental fibroblasts. How-
ever, the majority of iPSC clones contained both parental
fibroblasts and unique variants in variable numbers and
combinations (Figures 2A–2C). Although the highest vari-
ability was observed in the iPSCs carrying the POLG
p.P648R mutation (N6), these did not display a signifi-
cantly higher number of variants compared with the iPSCs
derived from control, mitochondrial, or nuclear groups
(Figure S5A).
We observed a general increase of heteroplasmy levels,
which, in some cases, led variants heteroplasmic in










































J1c4 LHON (#535000) MT-ND4 m.11778G>A
homoplasmic




H1at1 LHON (#535000) MT-ND1 m.3460G>A
homoplasmic
p.A52T Sendai virus fibroblasts 15M 1 60.6-Mb duplication
in 1p35.3p22.2
33M 0 normal Peron et al., (2020)
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fibroblasts A1 1 normal Auré et al. (2013)
Lorenz et al., (2017)
M5
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H1b NARP (#551500) MT-ATP6 m.9185T>C
homoplasmic
p.L220P retrovirus fibroblasts A2 1 normal
M6
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H1b NARP (#551500) MT-ATP6 m.9185T>C
homoplasmic
p.L220P retrovirus fibroblasts A3 1 normal






















































U5a1a1 PKAN (#234200) PANK2 c.569insA
homozygous




U4b1a DOA (#165500) OPA1 c.1334 G>A
heterozygous




H13a1a1 DOA (#165500) OPA1 c.1334 G>A
heterozygous




HV0b DOA (#165500) OPA1 c.1462A>G
heterozygous





H1aq DOA (#165500) OPA1 c.1484C>T
heterozygous




H1ab1 CPEO (#203700) POLG c.1943C>G
homozygous







J1c15 CPEO (#609286) TWNK c.907C>T
heterozygous
p.R303W Sendai virus fibroblasts #34 0 normal


































Figure 1. Effect of age, reprogramming
methods, and mitochondrial haplotype on
the number of mtDNA heteroplasmic vari-
ants in fibroblasts, iPSCs, and NPCs
(A) Elderly subjects presented higher number
of heteroplasmic variants in fibroblasts (p =
0.0132), but not in iPSCs (p = 0.135) and
NPCs (p = 0.10).
(B) The linear correlation between ages and
the accumulation of heteroplasmic variants
was statistically significant only in fibro-
blasts (adjusted R-squared = 0.376, p =
0.0068). Adjusted R-squared = 0.196, p =
0.065 in iPSCs; adjusted R-squared = 0.151,
p = 0.236 in NPCs.
(C) Number of heteroplasmic variants was
independent of the reprogramming method
in iPSCs (p = 0.08) and NPCs (p = 0.97).
(D) Haplotype J had significantly fewer vari-
ants in iPSCs (p = 0.031). Number of variants
in fibroblasts (p = 0.796) and NPCs (p =
0.241) was not related to a specific haplo-
type.fibroblasts to become homoplasmic in iPSCs as in C3 #7
(m.10377C>T from 23% to 99%–100%), M1 #32
(m.11150G>A from 53% to 95%), N5 #72-#75 (from 48%
to 98%–100%), and N6 #2-#4-#8 (from 21% to 100%) (Fig-
ures 2A–2C). This incremental shift of heteroplasmy was
also observed for the heteroplasmic pathogenic MELAS
(mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episodes) m.3243A>G mutation. In fact, iPSC
clones derived from M3 fibroblasts, showing a 24% muta-
tion load of the MELAS allele, displayed a broad distribu-
tion of the HF with one clone 100% wild-type (A), and
others ranging from 41% to 81% (B, L, and N) of the
mutant allele (Figure 2B, variant inmagenta). However, ex-
ceptions to this general increase were observed in M1 #20
(m.11150G>T from 53% to 0.65%; Figure S3A), in M4 A1
(m.10158T>C from 24% to 0.2%, m.11157T>C from 25%
to 0.2%, and m.13424T>C from 28% to 0.2%; Figure S3F),
in N2 13M (m.10861T>C from 14% to 0.3% and
m.16044T>C from 6% to 0.3%; Figure S4B) and in N3
#205 (m.13020T>C from 11% to 1%; Figure S4C). In
contrast, the Leber hereditary optic neuropathy (LHON)
m.11778G>A in M1 and m.3460G>A in M2, and the neu-
ropathy ataxia retinitis pigmentosa (NARP) m.9185T>C
in M4/M5/M6 remained homoplasmic in all iPSC clones
as in the original fibroblasts.mtDNA heteroplasmy and variants segregations from
iPSCs to NPCs
Sixteen iPSC clones, three in the control, five in the mito-
chondrial, and eight in the nuclear groups (Table 1), weredifferentiated in NPCs and checked for mtDNA private var-
iants heteroplasmy. Globally, 86 heteroplasmic variants
were observed in iPSCs/NPCs and the three groups did not
differ in terms of variants number (p = 0.676; not shown).
The largemajority of the variantswere shared between iPSCs
and NPCs: only one NPC clone (#72 N5) presented just its
own unique variants (Figure S4F), while other NPCs were
more heterogeneous (#68 C2, 13M N2, and #4 N6) sharing
two, two, and one variants with the iPSCs of origin, respec-
tively (Figures S2D, S4B, and S4I).
NPCs variants usually presented an HF similar to that of
the iPSCs of origin, and even in the case of increment/reduc-
tion this was of limited magnitude and consistent with the
direction of heteroplasmy change previously observed in
the reprogramming step (Figures 3A–3C). A few exceptions
were noted, as in M1 NPC #20 holding a variant with HF
increasing from 0.65% to 85%, whereas in M4 NPC A1 the
HF increasewas lessmarked (from6% to11%); both variants
were predicted to be benign. Moreover, C1 and N6 NPCs
showed, respectively, a private benign variant in the MT-TI
tRNA gene (6% HF) and a synonymous variant in the MT-
CYB gene (0.6% HF), present in the parental fibroblasts at
extremely lowHF (0.7%), but apparently absent in their cor-
responding iPSCs (Figures S2B and S4J).mtDNA localization and prediction of variants
transmitted in reprogramming and differentiating
step
Fifty-two out of 86 variants, with HF ranging from 0.2% to
100%, were transmitted during the reprogramming step,Stem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021 1957
Figure 2. Fibroblasts to iPSCs heteroplasmy shift
Variants’ HF fluctuations during the reprogramming step from fibroblasts to iPSCs in control (A), mitochondrial (B), and nuclear (C) groups.
Dots appearing in iPSC mean unique variants. Non-transmitted variants are highlighted with a straight line going to zero in iPSC. One color
represents one variant.without any obvious bias among the three groups (p = 0.3)
(Table S2). Specifically, eight variants were in the control,
23 in the mitochondrial, and 21 in the nuclear groups.
We observed 35 variants in protein-coding genes, 12
rRNA genes, three in tRNA genes, but only two in the D-
loop region (Figures 4A and S5B–S5D). MT-ND4, MT-ND5,
and MT-RNR2, the three largest mtDNA genes, presented
the greater number of variants, whereas MT-ATP6, MT-
CO3, MT-ND4L, and MT-ND6 did not show variants; MT-
TA,MT-TL1, andMT-TPwere the only tRNA genes carrying
variants (Figure 4B). The variants’ transmission seemed to
be independent from their pathogenicity in both control
and patient groups. Most of the transmitted variants were
predicted to be benign (24 of 38) and were in cells from
affected patients (Figures 4C and S5E–S5G), but neither
benign (p = 0.251) nor damaging (p = 0.428) nor non-cod-
ing (p = 0.809) variants were preferentially transmitted dur-
ing the reprogramming step.
In the differentiating step, 35 variants ranging from HF
0.2%–100%, out of 52, were transmitted from iPSCs to
NPCs: five in the control, 16 in the mitochondrial, and
14 in the nuclear groups (Table S3). The variants’ transmis-
sion was unaffected by the control/patient status of the
NPCs (p = 0.74), and most of the variants were located in1958 Stem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021protein-coding genes. The remaining variants were in
non-coding genes: two in the D-loop region, five in
rRNA, and three in tRNA genes (Figures 4D and S5H–S5J).
The majority of transmitted variants were in MT-ND4 and
MT-ND5 genes, and all protein-coding genes, except MT-
ATP6,MT-CO1,MT-CO3, andMT-ND3, presented with var-
iants;MT-TA andMT-TPwere the only tRNA genes carrying
variants (Figure 4E). Even in iPSC toNPC transition, despite
17 out of 28 variants being predicted to be benign (Figure 4F
and S5K–S5M), there was no difference in the transmission
of benign (p = 0.559), likely damaging (p = 0.285), or non-
coding (p = 0.621) variants in the three groups.
Analysis of variants unique in iPSCs and NPCs
The variant m.7824C>T in MT-CO2, causing the amino
acid change p.S80F predicted to be highly damaging (dis-
ease score 0.835 and Polyphen2 score 0.913), had high het-
eroplasmy levels (81% and 37%), in N4 iPSC clones #12
and #18 and derived NPC (72% and 47%), and was already
present at only 0.4% inN4 parental fibroblasts (Figures S4D
and S4E). Therefore, we focused on iPSCs unique variants,
comprising both somatic variants and variants arising dur-
ing reprogramming. We counted 34 unique variants: eight
in the control, six in the mitochondrial, and 20 in the
Figure 3. iPSCs to NPCs heteroplasmy shift
Variants’ HF fluctuations during the differentiation step from iPSCs to NPCs in control (A), mitochondrial (B), and nuclear (C) groups. Dots
appearing in NPC mean unique variants. Non-transmitted variants are highlighted with a straight line going to zero in NPC. One color
represents one variant.nuclear groups (Table S4). Although the average number of
unique variants was not dependent on the presence of
wild-type or mutated mitochondrial/nuclear DNA in the
starting cell lines (p = 0.096), we noticed the highest vari-
ability in the N6 iPSC clone. Then, we tested whether these
POLG-derived iPSCs accumulated more unique variants
compared with all other iPSCs, and we found a statistically
significant difference (Figure S5N). Five variants were in the
D-loop region, eight in rRNA genes, four in tRNA, and 17 in
protein-coding genes (Figure 5A). MT-DLOOP and MT-
RNR2 resulted in more variants, while MT-ATP8, MT-CYB,
MT-ND1, MT-ND3, and MT-ND4 did not have heteroplas-
mic variability; only MT-TA, MT-TH, MT-TL1, and MT-TP
tRNA genes showed the presence of variants (Figure 5B).
Annotation of the protein-coding variants revealed that
one was a stop-gain, three were synonymous, while 13
were nonsynonymous, 10 of which were predicted to be
deleterious (Figure 5C). However, we noticed that the na-
ture of a variant (p = 0.213 for the non-coding variants)
or its predicted pathogenicity (p = 0.888 and p = 0.920,
respectively, for the benign and damaging variants) didnot drive the occurrence as a unique variant in the three
groups. Finally, interrogation of the GenBank database
showed that 14 variants were never reported, whereas the
most represented variants in the database were in the D-
loop region and in rRNA genes (Table S4).
NPCs accumulated 31 unique variants (HF from 0.5% to
18.9%): seven in the control, four in the mitochondrial,
and 20 in the nuclear groups (Table S5). We did not notice
a significant difference in the average number between the
three groups (p = 0.26), even though roughly half of the
variants of the nuclear group were contributed by the N6
(POLG) patient. Five variants were located in the D-loop re-
gion, two in tRNA, three in rRNA genes, and 21 in protein-
coding genes (Figure 5D). MT-DLOOP and MT-CO1 accu-
mulated more variants, while we did not observe variants
in MT-ATP6, MT-ATP8, MT-ND1, MT-ND3, and MT-ND4L
genes; MT-TE and MT-TL1 were the only tRNA genes with
variants (Figure 5E). Notably, the MELAS m.3243A>G mu-
tation arose, at low heteroplasmy (1%), in C2 #68. Finally,
also for NPC unique variants, notwithstanding that 17 out
of 23 were predicted to be benign (Figure 5F), we failed toStem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021 1959
Figure 4. mtDNA localization and prediction of variants transmitted in reprogramming and differentiating steps in the three
groups
(A) Fifty-two heteroplasmic variants transmitted during the reprogramming step.
(B) Mitochondrial genes localization of transmitted variants in iPSCs.
(C) Predictions of transmitted variants in iPSCs.
(D) Thirty-five heteroplasmic variants transmitted in the differentiating step.
(E) Mitochondrial genes localization of transmitted variants in NPCs.
(F) Predictions of transmitted variants in NPCs.
syn, synonymous; nonsyn, nonsynonymous; b, benign; d, damaging.observe a significant difference in the occurrence of unique
benign (p = 0.402), damaging (p = 0.767), or non-coding
(p = 0.114) variants between controls and patients’ groups.
Ten variants, located in the MT-DLOOP and rRNA, were
never reported in GenBank (Table S5).Analysis of non-transmitted variants in iPSCs and
NPCs
Thirty-two fibroblast variants (HF range 0.5%–55%) were
non-transmitted in iPSC clones in a comparable way be-
tween groups (p = 0.357): five in the control, seven in the
mitochondrial, and 20 in the nuclear groups (Table S6).
One variant was in the D-loop region; nine in rRNA genes,
with the 16s rRNA resulting in the gene non-transmitting
the largest number of variants; four in the tRNA; and 18
in protein-coding genes, of which 13 were nonsynony-
mous predicted to likely be damaging (Figures S6A–S6C).
In particular, two reported pathogenic variants,
m.5540G>A with 5% HF (Bannwarth et al., 2013; Silvestri
et al., 2000) and m.8993T>C with 19.6% HF (Kara et al.,
2012; Weerasinghe et al., 2018), did not pass from C2
and M2 fibroblasts to iPSCs. Although 15 out of 22 non-
transmitted variants were predicted as damaging, we1960 Stem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021noticed a statistical difference only for the non-transmitted
non-coding variants among themitochondrial and the nu-
clear groups (p = 0.02), whereas there was no difference for
benign (p = 0.853) and damaging (p = 0.767) variants.
During the differentiation step, 16 variants with HF
ranging from 0.2% to 11% were non-transmitted: one in
the control, five in the mitochondrial, and 11 in the nu-
clear groups; the last two groups shared a variant in MT-
RNR2 (m.1693C>A) (Table S7). Importantly, also in this
step, we did not observe a bias in the non-transmission of
the variants among the three groups (p = 0.521). Eight var-
iants were in non-coding regions in tRNA/rRNA genes
(three in the D-loop region, one in a tRNA, and four in
rRNA genes) (Figures S6D and S6E), whereas nine affected
protein-coding genes, including four nonsynonymous var-
iants predicted as deleterious (Figure S6F). Neither non-
coding (p = 0.188), nor benign (p = 0.909), nor damaging
(p = 0.086) variants were preferentially non-transmitted.Functional studies of mtDNA mutations in NPCs
To verify functional consequences of predicted pathogenic
mtDNA mutations we used, as a paradigm, NPCs derived
from iPSCs carrying variable levels of the p.S80F mutation
Figure 5. mtDNA localization and prediction of unique variants in iPSCs and NPCs in the three groups
(A) Thirty-four heteroplasmic variants were unique in iPSCs clones.
(B) Mitochondrial genes localization of transmitted variants in iPSCs.
(C) Predictions of unique variants in iPSCs.
(D) Thirty-one heteroplasmic variants were unique in the NPCs clones.
(E) Mitochondrial genes localization of unique variants in NPCs.
(F) Predictions of unique variants in NPCs.
syn, synonymous; nonsyn, nonsynonymous; b, benign; d, damaging.(m.7824C>T) in theMT-CO2 subunit gene of cytochrome c
oxidase (COX), predicted to be highly pathogenic and
never reported in Mitomap. We tested two independent
NPCs (#12 and #18) obtained from patient N4, with 73%
or 47% HF. Oxygen consumption rate showed a significant
reduction of the maximal respiratory rate in NPC clone
#12, and to a lesser extent in clone #18, as compared
with control NPCs or NPCs derived from two clones
(G488R#12 and G488R#22), generated from a different pa-
tient carrying an OPA1 mutation identical (Iannielli et al.,
2018) to the one present in patient N4, but with a wild-
type mtDNA sequence (Figure 6).
DISCUSSION
Appearance of mtDNA variants during iPSCs reprogram-
ming and their differentiation into specific lineages is a
sensible area of investigation for the experimental and
therapeutic use of iPSCs. We showed that, at each step
from parental fibroblasts/PBMCs, to reprogrammed iPSCs,
and then differentiated NPCs, HF of mtDNA variants,
including those potentially pathogenic, fluctuate between
emerging or disappearing or undergoing drift. The dy-
namics of these fluctuationsmay include bottleneck events
but also genetic drifts in the absence of a clear purifying
selection.We performed deep mtDNA sequencing in several cell
types, obtained from both control individuals and patients
with mitochondrial diseases. The high coverage obtained,
especially in fibroblasts, allowed us to confidently identify
variants with a very low heteroplasmic load, missed by
standard sequencing technologies, demonstrating the exis-
tence of universal mtDNA heteroplasmy, due to both in-
herited and somatic variants (Payne et al., 2013; Wei
et al., 2019). We showed that low heteroplasmic variants
(<1%) can be consideredwith high confidence true variants
since those present with an extremely low HF (from 0.2%
to 1%) in fibroblasts were identified in derived iPSCs and/
or NPCs and unique variants were shared among different
iPSCs or NPCs, indicating their probable origin from the
parental fibroblasts. Fibroblasts are pooled cells with high
mtDNA sequence heterogeneity and certain variants,
even present at high HF in a single cell, ultimately appear
diluted or even absent in the cell culture. Thus, we might
consider as an initial bottleneck event the clonal nature
of iPSCs reprogramming from a single fibroblast, high-
lighting its parental heteroplasmic profile. Ultimately, the
mtDNA variants observed in the iPSCs may reflect either
true de novo events or pre-existing heteroplasmic variants
buried under the detection threshold in the parental fibro-
blasts, but expanding in the clonally reprogrammed cells.
Congruently, it was shown that MELAS iPSC clones shiftedStem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021 1961
Figure 6. MRR of NPC
Control (C2 #37), OPA1 p.G488Rmutation with (N4 #12 and N4 #18)
or without (G488R #12 and G488R #22; Iannielli et al., 2018)
p.S80F mutation in CO2 mtDNA sequence. Control = 100%MRR. *p <
0.05, ***p < 0.001. All measurements were performed in 30 repli-
cates for each sample. At least three different experiments in blind
conditions to the examiner were carried out on different days.either close to zero or to high mutant load during reprog-
ramming, whereas fibroblast cultures showed a wide spec-
trum of heteroplasmy states (Hämäläinen et al., 2013).
This scenario was already described and discussions
revolved around the issue of whether the iPSCs variants
were pre-existing and detectable in the original fibroblasts
cell culture or not (Kang et al., 2016; Perales-Clemente
et al., 2016).
Previous studies underlined the correlation of mtDNA
variants in iPSCs with the age of patients originating the
primary cell culture (Kang et al., 2016). We confirm this
age-related increase of mtDNA variants in fibroblasts, as
shown by simply comparing the young (aged 12–49 years)
and old (aged 50–80 years) subjects. However, we failed to
detect the same correlation either in iPSCs or in NPCs,
even if in Kang’s study there was also a consistent trend
in reducing the amount of variants across reprogramming
(see Figure 3E in Kang et al., 2016). The reprogramming
procedure implies a sort of rejuvenation process (Goya
et al., 2018) in which iPSCs derived from old individuals
could reset their genetic heritage through multiple pas-
sages and, in doing so, erase the mtDNA alterations accu-
mulated during aging in the parental fibroblasts. Our data
are consistent with the number of passages of the iPSCs1962 Stem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021(15–20), whereas those analyzed by Kang had a signifi-
cantly lower (2–4) number of passages (Kang et al., 2016),
when iPSCs display the greatest heterogeneity and vari-
ability (Volpato and Webber, 2020). The hypothesis of
germline purifying selection based on the functional
impact of mtDNAmutations has been previously proposed
in murine models, acting most efficiently against variants
affecting protein-coding genes (Stewart et al., 2008). Our
results to some extent provide the same indication of pref-
erential selection against mtDNA mutation in protein-en-
coding genes. It has also been reported that theMELASmu-
tation, affecting a tRNA, progressively reduced its
heteroplasmic load with increasing iPSCs passages in pro-
longed cell culture (Folmes et al., 2013). Thus, even if a pur-
ifying selection against specific damaging variants cannot
be excluded, we here demonstrated that pathogenic vari-
ants are present in iPSCs and maintained in derived
NPCs. Thismay suggest a different surveillancemechanism
to explain the vanishing of age-related differences, which
might go beyondmtDNA. It remains that iPSCs relymainly
on glycolysis, explaining the tolerance of damaging vari-
ants affecting the OXPHOS system. Further investigations
are required to fully understand the rejuvenation or purify-
ing selection.
The iPSCs carryinghaplogroup J1c, butneitherfibroblasts
nor NPCs, had a significantly reduced variants number
compared with the most frequent European haplogroup
H. This points to something happening at the reprogram-
ming step or in the culturing passages of iPSCs. The nuclear
background or the existence of an mtDNA pathogenic mu-
tationwere irrelevant as the threehaplogroup J1c caseswere
respectively a control and a LHON patient, in the young
group, and a Twinkle patient, in the old group. Haplogroup
J is solidly associated with LHON, as a background
enhancing penetrance (Carelli et al., 2006; Hudson et al.,
2007; Torroni et al., 1997). Haplogroup J has also been asso-
ciated with longevity in an Italian population (De Benedic-
tis et al., 1999), but not in others (Rose et al., 2001), and the
JT superhaplogroup has been proposed to be protective in
Parkinsondisease (Hudson et al., 2013). Testinghaplogroup
J in cybrids highlighted a slightly inefficient OXPHOS
compared with other haplogroups, in particular hap-
logroup H, which may enhance the pathogenicity of
LHON mutations, but in the long run accumulate less so-
matic mutations favoring longevity and protecting from
Parkinson (Gómez-Durán et al., 2012; Strobbe et al.,
2018). This seems recapitulated in the acutemodel of iPSCs
generation, as emphasizedbyour results of reducedpropen-
sity to accumulate mtDNA variants in haplogroup J.
Overall, most of the reported variants increased the level
of heteroplasmy from fibroblast to iPSCs. Once fixed in
iPSC clones, these variants were, in most cases, present
and maintained at a similar heteroplasmic level in NPCs,
suggesting that, during this transition, no major modula-
tions of mtDNA amount occur, although additional
mtDNA variants may arise. This latter event was, however,
mostly, but not exclusively, occurring in POLG mutant
cells, characterized by defective mtDNA replication. The
POLG mutation (Table 1), a homozygous p.P648R change
hitting the spacer domain of the protein, potentially alters
enzyme activity, processivity, DNA-binding affinity, or af-
fects interactions with the mitochondrial single-stranded
DNA-binding protein a partner protein, part of the mito-
chondrial ‘‘replisome’’ complex (Luo and Kaguni, 2005).
It is therefore conceivable to observe an increase in muta-
tion frequency in the POLG mutant cell line endowed
with a crippled enzyme. This does not exclude the already
mentioned pre-existence of buried variants emerging as
apparently de novo variants. In fact, in fibroblasts, we failed
to observe a difference in total variants load, which became
apparent in terms of de novo variants only after reprogram-
ming. A similar situation occurs in the single Twinkle iPSC
clone, another gene involved in mtDNA maintenance.
Remarkably, in POLG-, Twinkle-, and OPA1-derived iPSC
clones, we failed to observemtDNAdeletions, usually accu-
mulating in post-mitotic tissues of patients (Carelli and
Chan, 2014).
We did not observe the presence of recurrent mtDNA var-
iants, nor obviousmutational hot spots or genesmore prone
than others to genetic variation, except for the m.1693C>A
variant in the MT-RNR2, detected in three unrelated iPSCs.
This novel variant was absent in the Mitomap repository,
and was not recognized by previous studies of the iPSCs mi-
togenome (Kang et al., 2016; Perales-Clemente et al., 2016).
Most reported variants affected protein-coding genes and
roughly half of them were potentially damaging. As proof
of principle, we studied the p.S80F mutation in MT-CO2,
present at extremely low heteroplasmic level in OPA1 fibro-
blasts, and expanded during reprogramming in two inde-
pendent iPSCs clones and derived NPCs. This mtDNA
variant caused a severe impairment of the maximal respira-
tory capacity, which could cause, if unaware, a misinterpre-
tation of the functional effect of the OPA1 mutation.
Overall, we found about equal amounts of variants in
structural genes encoding OXPHOS subunits and in genes
dedicated to the mtDNA translation (tRNAs/rRNAs). This
contrasts with the total size of the protein-encoding genes
(11.3 kb), against the size of the translation-dedicated
mtDNA genes (3.9 kb), which may suggest some degree
of purifying selection mostly acting on protein-coding
genes (Stewart et al., 2008). It remains that clearly patho-
genic variants are tolerated during reprogramming and
subsequent differentiation. Interestingly, there seems to
be preferential occurrence of mtDNA variants hitting a
few specific tRNAs and, more consistently, the MT-RNR2.
Some of the tRNAs (MT-TI, MT-TW, MT-TH, MT-TA, MT-TE, MT-TP) are shared by Kang et al. (2016). However, it
is unclear if there is some selectivity in mtDNA mutagen-
esis or if some degree of purifying selection is acting
through reprogramming/differentiation, or if a combina-
tion of both mechanisms may occur.
Despite previous and the present studies reported the
importance of analyzing both the mitochondrial and nu-
clear genome in iPSCs, mtDNA sequencing is rarely incor-
porated in the quality control check of iPSCs (Attwood
and Edel, 2019; Doi et al., 2020; Doss and Sachinidis,
2019). Remarkably, the first iPSCs therapy for Parkinson
disease started in 2018 (http://www.cira.kyoto-u.ac.jp/e/
pressrelease/news/180730-170000.html) but the clinical
grade iPSCs characterization did not seem to include
mtDNA analysis. Likewise, various studies documenting
mitochondrial dysfunctions in neurodegenerative dis-
eases, such as multiple system atrophy (Monzio Compag-
noni et al., 2018), amyotrophic lateral sclerosis(Dafinca
et al., 2016), Parkinson disease (Little et al., 2018), and Alz-
heimer disease (Birnbaum et al., 2018), did not report
mtDNA analysis of iPSCs. We here showed that mtDNA
variants occur not only in iPSCs but also in NPCs, adding
concerns when working with this in vitro system.
Our study remarked that generation of iPSCs is consis-
tently affected by events of expansion/reduction or de novo
generation of heteroplasmic variants inmtDNA, potentially
deleterious, ultimately affecting the global healthiness of
the iPSCs. This has profound implications for further differ-
entiated cells or organoids (Lancaster and Knoblich, 2014)
used to model diseases, but particularly for in vivo therapeu-
tic use of iPSCs in humans, as for Parkinson patients (Fan
et al., 2020; Stoddard-Bennett and Pera, 2020). Furthermore,
it was recently shown that nonsynonymous mtDNA muta-
tions in iPSCsmay lead to neoantigens eliciting an immune
response, indicating that autologous iPSCs may not be
immunologically inert (Deuse et al., 2019).
In conclusion, the mtDNA sequence profile of iPSCs is an
unavoidable step to ensure that these cells are suitable for
modeling diseases and testing experimental treatments. A
systematic study of the dynamic changes inmtDNA variants
occurrence and segregation also provides a great opportunity
to better understand all issues related to universal hetero-
plasmy. Ultimately, checking genetic stability of iPSCs and
evaluating nuclear and mitochondrial genomes is of para-
mount importance forquality-grade iPSC-basedclinical trials.EXPERIMENTAL PROCEDURES
Genetic characterization of patients’ derived
fibroblasts
Fibroblasts derived from 13 patients affected bymitochondrial dis-
orders and five healthy age-matched subjects were included in this
study and obtained from the cell lines and DNA bank of pediatricStem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021 1963
movement disorders and mitochondrial diseases of the Telethon
Network of Genetic Biobanks (http://biobanknetwork.telethon.
it). Patients were classified into a mitochondrial group (M1 to
M6) with either homoplasmic or heteroplasmic mtDNA muta-
tions, or a nuclear group (N1 to N7) with mutations in nuclear
genes coding for mitochondrial proteins (Table1).
Generation and Characterization of iPSCs
We used either already generated or newly produced iPSCs. On
average, passages of iPSCs in culture were in the range between
15 and 20. Table 1 summarizes all the relevant information.
iPSCs for NARP mutation were generated from fibroblasts
derived from a three-generation family carrying the homoplasmic
m.9185T>C mutation. Subjects M4, M5, and M6 in Table 1 corre-
spond to patient A1 (patient III-6), patient A2 (daughter of A1, pa-
tient 1, IV-5), and patient A3 (third-degree cousin of A2, patient 2,
V-5) respectively (Auré et al., 2013). iPSCs for patient M4 were
generated by episomal plasmid, and for patients M5 and M6 by
transduction with retrovirus. Characterization andmtDNA Sanger
sequence analysis were performed as reported (Lorenz et al., 2017).
iPSCs for MELAS mutation were generated from fibroblasts as
described (Hämäläinen et al., 2013). The mutation load was deter-
mined in fibroblasts and derived iPSCs by minisequencing (Suo-
malainen et al., 1993). Available clones reported in Table 1 have
the following heteroplasmic levels: #A = 4.2%, #B = 2.5%, #L =
79.7%, and #N7 = 2.5%. iPSCs for dominant optic atrophy
(DOA) and pantothenate kinase-associated neurodegeneration
(PKAN) were generated from primary fibroblasts as described (Ian-
nielli et al., 2018; Orellana et al., 2016). New iPSCs for DOA and
LHON were generated and characterized as described (Iannielli
et al., 2018; Peron et al., 2020).
CGH array
Integrity of nuclear DNA was verified by array comparative
genomic hybridization (CGH) as described (Peron et al., 2020).
mtDNA sequencing
Sequence analysis of the entire mtDNA molecule was performed
by the NGS approach (Caporali et al., 2018). The primers used to
amplify the mtDNA molecule in two segments are strategically
located outside the regions involved in the generation of break-
points underlying mtDNA deletions. The NGS libraries were con-
structed by Nextera XT (Illumina) and paired end sequenced on
MiSeq System (Illumina), usingMiSeq Reagent Kit v3 (600 cycles).
Fastq files were analyzed with MToolBox v1.1 and v.1.2 (https://
github.com/mitoNGS/MToolBox) (Calabrese et al., 2014). Only
mono-allelic SNVs (single nucleotide variant) with a read depth
R100 and a base quality score R30 were retained. All private het-
eroplasmic SNVs were visually inspected with the tool IGV (Inte-
grative Genome Viewer: https://software.broadinstitute.org/
software/igv/) in order to check the variants’ strand bias, and
strongly unbalanced variants were discarded. Reads depths (total,
forward, and reverse) for unique variants with HF % 2% are re-
ported in Table S8.
Nonsynonymous variants with a disease score >0.43 were pre-
dicted to be deleterious, while for tRNA variants we considered
the MitoTIP prediction.1964 Stem Cell Reports j Vol. 16 j 1953–1967 j August 10, 2021Statistical analysis
Statistical analyses were performed with GraphPad Prism 6.0. Dif-
ferences betweenmean values of variants with respect to age of cell
line donors and to reprogramming method were assessed by the
Mann-Whitney unpaired t test. Univariate linear regression anal-
ysis was performed to assess the effect of age on the number of var-
iants in the cell lines. Differences andmultiple comparisons in the
three groups were estimated with the Krustal-Wallis, one-way
ANOVA test. A p value %0.05 was considered significant.Determination of respiratory activity
Oxygen consumption rate (OCR) was measured in DOA and con-
trol NPCs with an XF96 Extracellular Flux Analyzer (Seahorse
Bioscience, Billerica, MA). NPCs were seeded at a density of
20,000 cells/well and measurement was performed as described
(Invernizzi et al., 2012). Maximal respiration rate (MRR) was calcu-
lated as percentage of control.Data and code availability
The SRA (Sequence ReadArchive) accessionnumber for the data re-
ported in this paper is PRJNA706687.SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/
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